Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Short term Debt: 2018-2022

Historic Short term Debt for Protagonist Therapeutics (PTGX) over the last 5 years, with Dec 2022 value amounting to $69,000.

  • Protagonist Therapeutics' Short term Debt fell 87.50% to $10,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $10,000, marking a year-over-year decrease of 87.50%. This contributed to the annual value of $69,000 for FY2022, which is 92.32% down from last year.
  • Per Protagonist Therapeutics' latest filing, its Short term Debt stood at $69,000 for FY2022, which was down 92.32% from $899,000 recorded in FY2021.
  • Protagonist Therapeutics' Short term Debt's 5-year high stood at $2.7 million during FY2020, with a 5-year trough of $69,000 in FY2022.
  • Moreover, its 3-year median value for Short term Debt was $899,000 (2021), whereas its average is $1.2 million.
  • In the last 5 years, Protagonist Therapeutics' Short term Debt surged by 116.48% in 2020 and then plummeted by 92.32% in 2022.
  • Over the past 5 years, Protagonist Therapeutics' Short term Debt (Yearly) stood at $1.1 million in 2018, then grew by 18.94% to $1.3 million in 2019, then surged by 116.48% to $2.7 million in 2020, then plummeted by 67.09% to $899,000 in 2021, then tumbled by 92.32% to $69,000 in 2022.